The first and only oral JAK inhibitor approved for adults with active psoriatic arthritis1

Full Prescribing Information

Assisting with access and affordability for patients on XELJANZ and XELJANZ XR

The recommended dose of XELJANZ is 5 mg twice daily and of XELJANZ is 11 mg once daily used in combination with nonbiologic DMARDs. The efficacy of XELJANZ/XELJANZ XR as monotherapy has not been studied in psoriatic arthritis.1

XELJANZ 11 mg administered once daily is pharmacokinetically equivalent to XELJANZ 5 mg administered twice daily. The recommended dose in patients with moderate to severe renal impairment and moderate hepatic impairment is XELJANZ 5 mg once daily.1

DMARD=disease-modifying antirheumatic drug; JAK=Janus kinase; PsA=psoriatic arthritis.